Marker Therapeutics (MRKR) Stock Price, News & Analysis

Company Overview

Marker Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers. The company has initiated early-phase clinical studies in patients with HPV16-positive head and neck cancers, as well as exploratory trials in other solid tumor indications. Marker conducts its research and development activities at its headquarters in Houston, Texas, and collaborates with academic and clinical partners across the United States to support trial enrollment and translational research efforts.

Founded in 2019 through a corporate reorganization and public listing, Marker Therapeutics transitioned its focus from earlier-stage RNA-based programs to cell-based immunotherapies. The company is guided by a management team experienced in cell therapy development, process scale-up and regulatory strategy. With an emphasis on personalized medicine, Marker is advancing its pipeline toward later-stage studies and exploring combination approaches alongside established oncology agents.

Key Stats

• Today's Range: $0.91 to $0.95
• 50-Day Range: $0.85 to $1.92
• 52-Week Range: $0.81 to $5.95
• Volume: 185,599 shs
• Average Volume: 797,987 shs
• Market Capitalization: $12.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.17
• Consensus Rating: Strong Buy

Marker Therapeutics Stock Analysis - MarketRank™

Marker Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 289th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Marker Therapeutics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Marker Therapeutics has a consensus price target of $13.17, representing about 1,311.2% upside from its current price of $0.93.

Amount of Analyst Coverage

Marker Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Marker Therapeutics are expected to decrease in the coming year, from ($0.65) to ($2.19) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Marker Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Marker Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Marker Therapeutics has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.59% of the float of Marker Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Marker Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Marker Therapeutics has recently increased by 251.32%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Marker Therapeutics does not currently pay a dividend.

Dividend Growth

Marker Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -0.75

Percentage of Shares Shorted

13.59% of the float of Marker Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Marker Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Marker Therapeutics has recently increased by 251.32%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.45

News Sentiment

Marker Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Marker Therapeutics this week, compared to 1 article on an average week.

Search Interest

9 people have searched for MRKR on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Marker Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Marker Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.80% of the stock of Marker Therapeutics is held by insiders.

Percentage Held by Institutions

Only 22.39% of the stock of Marker Therapeutics is held by institutions.

MRKR Stock Analysis - Frequently Asked Questions

How have MRKR shares performed this year?

Marker Therapeutics' stock was trading at $3.11 at the start of the year. Since then, MRKR shares have decreased by 70.0% and is now trading at $0.9330.

How were Marker Therapeutics' earnings last quarter?

Marker Therapeutics, Inc. (NASDAQ:MRKR) announced its earnings results on Thursday, August, 14th. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.26. The company had revenue of $0.86 million for the quarter, compared to analyst estimates of $0.72 million. Marker Therapeutics had a negative net margin of 271.12% and a negative trailing twelve-month return on equity of 114.59%.

Who are Marker Therapeutics' major shareholders?

Top institutional shareholders of Marker Therapeutics include Jane Street Group LLC (0.19%).
View institutional ownership trends.

How do I buy shares of Marker Therapeutics?

Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Marker Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Marker Therapeutics investors own include SCYNEXIS (SCYX), Tesla (TSLA), Meta Platforms (META), Pfizer (PFE), NVIDIA (NVDA), Viking Therapeutics (VKTX) and OPKO Health (OPK).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MRKR
• CIK: 1094038
• Web: www.markertherapeutics.com
• Phone: (713) 400-6400
• Fax: N/A
• Employees: 60
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Marker Therapeutics: $13.17
• High Price Target: $19.00
• Low Price Target: $8.00
• Potential Upside/Downside: +1,308.2%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.73 million
• Net Margins: -271.12%
• Pretax Margin: -270.17%
• Return on Equity: -114.59%
• Return on Assets: -90.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.45
• Quick Ratio: 3.45

Sales & Book Value

• Annual Sales: $6.59 million
• Price / Sales: 1.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.73 per share
• Price / Book: 0.54

Miscellaneous

• Outstanding Shares: 12,940,000
• Free Float: 11,930,000
• Market Cap: $12.10 million
• Optionable: Not Optionable
• Beta: 1.52